Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

Ryuji Yasumatsu, Takahiro Wakasaki, Kazuki Hashimoto, +5

Head & Neck

Individualized circulating tumor <scp>DNA</scp> monitoring in head and neck squamous cell carcinoma

Ryunosuke Kogo, Tomomi Manako, Takeshi Iwaya, +9

Cancer Medicine

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda, +8

Cancers

Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy

Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, +6

In Vivo

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

Takahiro Wakasaki, Tomomi Manako, Ryuji Yasumatsu, +12

PLoS ONE

Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma

Ryutaro Uchi, Rina Jiromaru, Ryuji Yasumatsu, +8

Anticancer Research

Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, +6

In Vivo

Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study

Takafumi Nakano, Ryuji Yasumatsu, Kazuki Hashimoto, +14

Anticancer Research

Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events

Ryuji Yasumatsu, Mioko Matsuo, Takahiro Wakasaki, +7

Acta Oto-Laryngologica